idarucizumab

Ligand id: 8298

Name: idarucizumab

References
1. Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S. (2014)
Reversal agents in development for the new oral anticoagulants.
Postgrad Med126 (7): 19-24. [PMID:25387210]
2. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, Lang B, Ramael S, Reilly P. (2015)
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
Thromb. Haemost.113 (5) [Epub ahead of print]. [PMID:25789661]
3. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Terleira-Fernandez AI, Vargas-Castrillon E. (2014)
Specific antidotes in development for reversal of novel anticoagulants: a review.
Recent Pat Cardiovasc Drug Discov9 (1): 2-10. [PMID:25494843]
4. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. (2013)
A specific antidote for dabigatran: functional and structural characterization.
Blood121 (18): 3554-62. [PMID:23476049]
5. Schiele F, van Ryn J, Litzenburger T, Ritter M, Seeliger D, Nar H. (2015)
Structure-guided residence time optimization of a dabigatran reversal agent.
MAbs, : 0 [Epub ahead of print]. [PMID:26047352]
6. Van Ryn J, Park JE, Hauel N, Kunz U, Litzenburger T, Canada K, Singh S, Waterman A. (2013)
Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds.
Patent number: US8486398. Assignee: Boehringer Ingelheim International Gmbh. Priority date: 20/01/2010. Publication date: 16/07/2013.